Perrigo Company plc Announces The Transfer Of Development Asset ELND005 To Transition Therapeutics Inc.

[PR Newswire] – TASE) announced today that it entered into a series of agreements with existing collaboration partner, Transition Therapeutics Inc. (TTHI), to progress the clinical development of ELND005 (Scyllo-inositol) in a number of important indicat more

View todays social media effects on TTHI

View the latest stocks trending across Twitter. Click to view dashboard

See who Transition is hiring next, click here to view